Pharmaceutical company Pfizer and two subsidiaries are paying $345 million for a settlement to significantly increase the price of anti-allergy injection EpiPen. That drug was marketed years ago by pharmaceutical company Mylan, which was merged with Pfizer’s subsidiary Upjohn last year. In 2016, prices suddenly rose by hundreds of percent.
–
The case caused a lot of commotion in the United States at the time. There is now an alternative to the life-saving lancing device against dangerous allergic reactions. But that wasn’t the case then. People who had to buy the drug were therefore saddled with a lot of extra costs.
“No guilt known”
Paying out hundreds of millions of dollars in compensation doesn’t end the matter. A procedure is also underway by insurers and pension funds, among others, who also claim to have been duped. No settlement has yet been reached.
Mylan has faced many accusations over the years in the EpiPen lawsuits. Recently, the issue has centered on claims that Mylan allegedly paid rival Teva in a settlement over something else to suspend development of a cheaper alternative to EpiPen. A Pfizer spokesperson said that the company pleads no guilt and remains convinced that it has acted correctly.
– .
